Skip to main content
Veterinary Medicines

VECOXAN 2.5 MG/ML ORAL SUSPENSION FOR LAMBS AND CALVES

Authorised
  • Diclazuril

Product identification

Medicine name:
VECOXAN 2.5 MG/ML ORAL SUSPENSION FOR LAMBS AND CALVES
Vecoxan 2,5 mg/ml Suspension zum Eingeben für Kälber und Lämmer
Active substance:
  • Diclazuril
Target species:
  • Cattle (calf)
  • Sheep (lamb)
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Diclazuril
    2.50
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Oral suspension
Withdrawal period by route of administration:
  • Oral use
    • Cattle (calf)
      • Meat and offal
        0
        day
    • Sheep (lamb)
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP51AJ03
Authorisation status:
  • Valid
Authorised in:
  • Austria
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Intervet Ges.m.b.H.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Intervet Productions S.A.
Responsible authority:
  • Austrian Agency For Health And Food Safety
Authorisation number:
  • 8-00709
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0113/001
Concerned member states:
  • Austria
  • Belgium
  • Czechia
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Luxembourg
  • Netherlands
  • Norway
  • Portugal
  • Slovakia
  • Spain

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 18/10/2024
Updated on: 21/11/2024

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 18/10/2024
Updated on: 21/11/2024

Labelling

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 18/10/2024
Updated on: 21/11/2024
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."